Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30815826 | 1.00 | LMNA (0.61) | LMNAGLAPOLBGAASMARCA2 | |
| Hydrochloric Acid SCHEMBL3107661 | 0.99 | LMNA (0.64) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL8109087 | 0.92 | LMNA (0.51) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL5290618 | 0.85 | LMNA (0.42) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL13941828 | 0.84 | LMNA (0.68) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL8109101 | 0.83 | LMNA (0.39) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL3921653 | 0.82 | GLA (0.64) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL14292897 | 0.81 | LMNA (0.63) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL8116591 | 0.81 | GLA (0.63) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL11046169 | 0.78 | POLB (0.97) | LMNAGLAPOLBGAASMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178864-B1 | Process for the preparation of alfuzosin hydrochloride | CIPLA LTD (IN) | 2014-07-23 | — | — | EP | claimed |
| US-8716476-B2 | Process for the preparation of alfuzosin hydrochloride | CIPLA LIMITED (IN) | 2014-05-06 | — | — | US | claimed |
| US-20100256370-A1 | Process for the Preparation of Alfuzosin Hydrochloride | CIPLA LIMITED (IN) | 2010-10-07 | — | — | US | claimed |
| EP-2178864-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN HYDROCHLORIDE | Cipla Limited (IN) | 2010-04-28 | — | — | EP | claimed |
| WO-2009016387-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN HYDROCHLORIDE | CIPLA LIMITED (IN) | 2009-02-05 | — | — | WO | claimed |
| WO-2008114272-A2 | PROCESS FOR PREPARING ALPUZOSIN AND CRYSTALLINE ALFUZOSIN HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-09-25 | — | — | WO | claimed |
| WO-2007144699-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (US) | 2007-12-21 | — | — | WO | claimed |
| US-20070105880-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (IN) | 2007-05-10 | — | — | US | claimed |
| WO-2006090268-A2 | PROCESSES FOR THE PREPARATION OF ALFUZOSIN AND SALTS THEREOF AND NOVEL CRYSTALLINE FORMS OF ALFUZOSIN | GLENMARK PHARMACEUTICALS LIMITED (US) | 2006-08-31 | — | — | WO | claimed |
| CN-113801069-B | Alfuzosin hydrochloride intermediate compound | 鲁南制药集团股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023179068-A1 | DRUG INTERMEDIATE AND SYNTHETIC METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHETIC METHOD THEREFOR | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| CN-113801069-A | Alfuzosin hydrochloride intermediate compound | 鲁南制药集团股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| EP-2178864-B1 | Process for the preparation of alfuzosin hydrochloride | CIPLA LTD (IN) | 2014-07-23 | — | — | EP | disclosed |
| EP-2178864-B1 | Process for the preparation of alfuzosin hydrochloride | CIPLA LTD (IN) | 2014-07-23 | — | — | EP | disclosed |
| WO-2007069050-A2 | PROCESSES FOR THE PREPARATION OF ALFUZOSIN | WOCKHARDT LTD. (IN) | 2007-06-21 | — | — | WO | disclosed |
| US-20070105880-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| US-20070105880-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| US-20070105880-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| WO-2006090268-A2 | PROCESSES FOR THE PREPARATION OF ALFUZOSIN AND SALTS THEREOF AND NOVEL CRYSTALLINE FORMS OF ALFUZOSIN | GLENMARK PHARMACEUTICALS LIMITED (US) | 2006-08-31 | — | — | WO | disclosed |
| US-4315007-A | HYPOTENSIVE, CARDIOVASCULAR DISORDERS | SYNTHELABO (FR) | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256370-A1 | Process for the Preparation of Alfuzosin Hydrochloride | NEFM, HNMT, EPM2A | LMNA 84/4885GLA 3710/4885POLB 2927/4885 |
| US-20070105880-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | LPXN, PSAP, GYPA | LMNA 1437/4885GLA 2104/4885POLB 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.